Publix Comparable Sales Slip 0.6% in Quarter
The grocer's third-quarter results reflect lower drug prices under a Medicare change and softer consumer spending.
Updated on Nov. 2, 2026 in Economic Indicators
Live Poll
Are you spending less on groceries than you did a year ago?
Publix Super Markets reported third-quarter sales of $15.5 billion for the period ended Sept. 26, up 1% from the prior year, while comparable-store sales decreased 0.6%. Net earnings fell 9.9% to $1.1 billion, and earnings per share were 33 cents, down from 37 cents.
Why it matters
The comparable-store decline was attributed primarily to the Medicare maximum fair price change effective Jan. 1, 2026, which reduced prices for 10 drugs, along with economic conditions affecting consumer spending. The results show how federal drug pricing policy can weigh on a major Florida-based grocer's pharmacy-linked sales even as total sales rise.
Publix reported nine-month sales of $47.4 billion, up 1.4% from $46.8 billion, and nine-month comparable-store sales fell 0.4%. The breakdown between drug-pricing effects and consumer spending in the decline has not been separated in the reported figures.
The players
Publix Super Markets
A Lakeland, Florida-based employee-owned supermarket chain that operates stores across the Southeast and reports results to its associates and board.
The details
Publix attributed the comparable-store decline primarily to the Medicare maximum fair price change, which lowered prices on 10 drugs starting Jan. 1, 2026, and to economic conditions. The company's stock, which is not publicly traded and is available only to current associates and board members, decreased from $19.60 to $18.70 per share effective Nov. 1.
Timeline
Jan. 1, 2026: Medicare maximum fair price change took effect, reducing prices for 10 drugs.
Sept. 26, 2026: Publix's third quarter ended with reported sales and earnings.
Nov. 1, 2026: Publix stock price decreased to $18.70 per share.
Macro View
The Medicare maximum fair price provisions, enacted under the Inflation Reduction Act, are now reaching retail pharmacy revenue, and Publix's 0.6% comparable-store decline is an early corporate data point on that effect. Grocers with large pharmacy operations in Florida and across the Southeast may see similar pressure on reported sales as additional drugs come under negotiated prices.
Shoppers at Publix may notice steadier prices on the 10 drugs affected by the Medicare change, even as the chain's overall store sales growth has slowed to 1% for the quarter. Households in Florida and the Southeast should watch whether the company's store-level pricing shifts as broader economic pressure on spending continues.
The takeaway
Publix's results show that federal drug-pricing changes can cut a retailer's reported sales even when total revenue still grows. Readers tracking grocery and pharmacy costs should expect pricing effects to appear gradually across the sector as more negotiated drug prices take hold.
Further reading
Explore more in Economic Indicators for context on the economic conditions weighing on consumer spending in Florida.
Live Poll
Are you spending less on groceries than you did a year ago?
